OTC Monograph User Fees Inspire Wary Support From Industry

Executives from OTC drug manufacturers list numerous doubts about the equity and effectiveness of a potential program that would impose user fees on firms that make or market monograph drugs, the vast majority of nonprescription pharmaceutical products.